SkinCure Oncology, the provider of a popular nonsurgical skin cancer treatment known as Image-Guided SRT, announced on March 6, 2026, that it has filed a lawsuit in federal court. The company is seeking an emergency injunction to stop new Medicare policies that would significantly limit patient access to this technology. The lawsuit specifically names the Department of Health and Human Services (HHS) led by Secretary Robert F. Kennedy, Jr. and the Centers for Medicare and Medicaid Services (CMS) under Administrator Dr. Mehmet Oz as defendants.
The legal battle centers on two major changes. First, Medicare intends to limit coverage for the ultrasound imaging part of the treatment; a tool doctors use to see exactly where the cancer is during each session. Second, a new rule would require dermatologists to complete additional residency programs in radiation oncology to continue providing the service. SkinCure Oncology argues these requirements are “arbitrary and capricious” because such training programs for dermatologists do not actually exist; which would effectively ban them from offering the treatment to their patients.
Understanding the Potential Impact on Patient Care and Capital Flow
Image-Guided SRT has grown rapidly as a preferred alternative to Mohs surgery, which involves cutting out cancerous tissue. With over 140,000 patients treated and a 99.8% satisfaction rate, the technology represents a significant shift in the dermatology market. If the current Medicare changes are allowed to proceed, the financial viability for private dermatology practices to offer this service would likely collapse. This would create a massive shift in capital flow; forcing patients back toward traditional surgery and potentially increasing wait times at specialized cancer centers.
Competitive positioning is at the heart of this regulatory dispute. SkinCure Oncology alleges that a small group of medical organizations is trying to push through these rules to eliminate competition from nonsurgical options. By making the treatment essentially impossible to bill for or legally perform, the new policy could protect the market share of surgical specialists. The lawsuit asserts that federal contractors do not have the authority to override state laws that define what a licensed doctor can or cannot do in their local practice.
Why This Legal Move Matters to Every Senior and Doctor
If you have ever had a medical bill denied because of a “coding change,” you know how frustrating this can be. But what is happening here is much bigger than a billing error. Imagine you found a treatment for skin cancer that didn’t require a scalpel and had a 99% cure rate, only to be told your doctor can’t offer it anymore because of a rule that requires them to take a class that doesn’t exist. That is exactly what SkinCure Oncology is fighting.
This is a classic “turf war” in the medical world. On one side, you have high-tech, nonsurgical options that are becoming very popular. On the other, you have traditional surgical methods that have been the standard for decades. When names like RFK Jr. and Dr. Oz are in the headlines, it can feel political; but for the average person, this is about choice. If the government can effectively ban a treatment by making the training impossible to get, it sets a dangerous precedent. It means that even if a treatment is safe and successful, a few pen strokes in Washington could take it away. This lawsuit is a necessary “firewall” to ensure that the progress we have made in “scalpel-free” cancer care isn’t erased overnight.
Sources
- SkinCure Oncology: Federal Lawsuit Against HHS and CMS March 6, 2026
- CMS: Local Coverage Determination L40193 for Superficial Radiation Therapy
- GentleCure: Clinical Data and Research on Image-Guided SRT Efficacy
- Sensus Healthcare: Regulatory Updates for SRT and Medicare Compliance 2026
- Journal of Clinical and Aesthetic Dermatology: 6-Year Cure Rates for IGSRT
Editorial Disclosure
This report is for informational and educational purposes only. This article includes subjective analysis and expert commentary from the writer. It is based on verified press releases and corporate announcements. It is not intended to provide financial, investment, or legal advice. All reporting is based on verified online sources as of March 7, 2026. Please read our full Disclaimer.
